

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Approval Package for:**

***APPLICATION NUMBER:***

**19-653/S-023 & 19-697/S-019**

***Trade Name:*** Ortho-Cyclen 0.25mg/0.035mg

Ortho Tri-Cyclen 0.18mg/0.035mg,  
0.215mg/0.035mg, 0.25mg/0.035mg

***Generic Name:*** norgestimate/ethinyl estradiol tablets

***Sponsor:*** Johnson RW

***Approval Date:*** 09/30/1999

***Indications:*** Ortho-Cyclen & Ortho Tri-Cyclen: For the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Ortho Tri-Cyclen: For the treatment of moderate acne vulgaris in females, greater than or equal to 15 years of age, who have no known contradictions to oral contraceptive therapy, desire contraception, have achieved menarche and are unresponsive to topical anti-acne medications.

# CENTER FOR DRUG EVALUATION AND RESEARCH

*APPLICATION NUMBER:*  
**19-653/S-023 & 19-697/S-019**

## CONTENTS

### Reviews / Information Included in this NDA Review.

<b>Approval Letter</b>	<b>X</b>
<b>Approvable Letter</b>	
<b>Labeling</b>	
<b>Summary Review</b>	
<b>Officer/Employee List</b>	
<b>Office Director Memo</b>	
<b>Cross Discipline Team Leader Review</b>	
<b>Medical Review(s)</b>	
<b>Chemistry Review(s)</b>	<b>X</b>
<b>Environmental Assessment</b>	
<b>Pharmacology Review(s)</b>	
<b>Statistical Review(s)</b>	
<b>Microbiology Review(s)</b>	
<b>Clinical Pharmacology/Biopharmaceutics Review(s)</b>	
<b>Risk Assessment and Risk Mitigation Review(s)</b>	
<b>Proprietary Name Review(s)</b>	
<b>Administrative/Correspondence Document(s)</b>	<b>X</b>

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*  
**19-653/S-023 & 19-697/S-019**

**APPROVAL LETTER**

201

NDA 19-653/S-023  
NDA 19-697/S-019

SEP 30 1999

R.W. Johnson Pharmaceutical Research Institute  
Attention: Donna Panasewicz  
Director, Regulatory Affairs  
Route 202  
P.O. Box 300  
Raritan, NJ 08869-0602

Dear Ms. Panasewicz:

Please refer to your supplemental new drug applications dated May 14, 1999, received May 17, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Ortho-Cyclen® (noregestimate/ethinyl estradiol) Tablets, Ortho Tri-Cyclen® (noregestimate/ethinyl estradiol) Tablets.

We note that these supplements were submitted as 'Special Supplement - Changes Being Effected' under 21 CFR 314.70(c).

These supplemental new drug applications provide for an additional analytical testing laboratory site. Your submission stated June 14, 1999 as the implementation date for the change.


We have completed the review of these supplemental applications and they are approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Jennifer Mercier, Regulatory Project Manager, at (301) 827-4260.

Sincerely,

9/30/99



Moo-Jhong Rhee, Ph.D.  
Chemistry Team Leader, for the  
Division of Reproductive and Urologic Drug  
Products, (HFD-580)  
DNDC II, Office of New Drug Chemistry  
Center for Drug Evaluation and Research

cc:

Archival NDAs 19-653, 19-697

HFD-580/Div. Files

HFD-580/J.Mercier

HFD-580/Reviewers and Team Leaders

HFD-095/DDMS-IMT

HFD-820/DNDC Division Director

DISTRICT OFFICE

Drafted by: JM/September 27, 1999

Initialed by: Rumble9.28.99/Lin9.29.99/Rhee9.29.99/Rarick9.29.99

final: September 30, 1999

filename: 19697SMU.WPD

APPROVAL (AP)

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*  
**19-653/S-023 & 19-697/S-019**

**CHEMISTRY REVIEW(S)**

201

**CHEMIST REVIEW  
OF SUPPLEMENT**

1. **ORGANIZATION:** DRUDP HFD-580
2. **NDA NUMBER:** 19-697/SCM-019
3. **SUPPLEMENT NUMBERS/DATES:**  
 Letterdate: 14-MAY-1999  
 Stampdate: 17-MAY-1999
4. **AMENDMENTS/REPORTS/DATES:**  
 Letterdate:  
 Stampdate:
5. **RECEIVED BY CHEMIST:** 19-MAY-1999

**6. APPLICANT NAME AND ADDRESS:**

R.W. Johnson Pharmaceutical Research Institute  
 920 Route 202 South  
 P.O. Box 300  
 Raritan, NJ 08869-0602

**7. NAME OF DRUG:**


Ortho Tri-Cyclen Tablets

**8. NONPROPRIETARY NAME:**


Norgestimate/ethinyl estradiol (NGM/EE)

**9. CHEMICAL NAME/STRUCTURE:**

- a. Norgestimate: a) (+)-13-Ethyl-17-hydroxy-18,19-dinor-17 $\alpha$ -pregn-4-en-20-yn-3-one oxime acetate  
 b) 18,19-Dinor-17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-, oxime, (17 $\alpha$ )-(+)



- b. Ethinyl estradiol: a) 19-Nor-17 $\alpha$ -pregn-1,3,5(10)-trien-20-yne-3,17-diol  
 b) 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17 $\alpha$ )



**10. DOSAGE FORM(S):**

Tablet

**11. POTENCY:**

180  $\mu$ g /35  $\mu$ g, 215  $\mu$ g /35  $\mu$ g, and 250  $\mu$ g /35  $\mu$ g Norgestimate/ethinyl estradiol

**12. PHARMACOLOGICAL CATEGORY:**

Progestin, estrogen/Contraception

**13. HOW DISPENSED:**

RX

**14. RECORDS & REPORTS CURRENT:**

Yes

**15. RELATED IND/NDA/DMF:**

NDA 19-653/SCM-023

**16. SUPPLEMENT PROVIDES FOR:**

An additional analytical testing laboratory site.

**17. COMMENTS**

This supplement has been filed to provide for an additional analytical testing laboratory site at . The sponsor has met all the criteria for this supplement to qualify as a CBE supplement under PAC-ALTS (Postapproval Changes-Analytical Testing Laboratory Sites). An EER was submitted on September 23, 1999 and returned as acceptable on September 23, 1999, based on profile (see attached EER).

**18. CONCLUSIONS AND RECOMMENDATIONS:**

This CBE Supplement may be approved. **Issue an approval letter.**

**19. REVIEWER NAME**

David T. Lin, Ph.D.  
Review Chemist

**SIGNATURE**

*David T. Lin*  
9/24/99

**DATE COMPLETED**

24-SEP-1999

cc: Original: NDA 19-697/SCM-019

HFD-580/Division File  
HFD-580/JMercier  
HFD-580/MRhee/DLin

INIT by MJ Rhee

*MJRhee* 9/24/99

Filename: S19697.019 (doc)

23-SEP-1999

FDA CDER EES  
ESTABLISHMENT EVALUATION REQUEST  
DETAIL REPORT

Page 1 of 1

Application: NDA 19697/019  
Stamp: 17-MAY-1999  
Regulatory Due: 17-SEP-1999  
Applicant: JOHNSON RW  
RT 202 SOUTH  
RARITAN, NJ 088690602

Action Goal:  
District Goal: 13-AUG-1999  
Brand Name: ORTHO TRI-CYCLEN  
Estab. Name:  
Generic Name: ETHINYL  
ESTRADIOL/NORGESTIMATE

Priority: 3S  
Org Code: 580

Dosage Form: (TABLET)  
Strength: SEE COMMENTS

Application Comment: THE TABLET STRENGTHS ARE: 180 MG /35 MG, 215 MG /35 MG, AND 250 MG /35 MG NORGESTIMATE/ETHINYL ESTRADIOL. THIS SUPPLEMENT IS FOR AN ADDITIONAL ANALYTICAL TESTING SITE. IT IS RELATED TO NDA 19-653/S-023. (on 23-SEP-1999 by D. LIN (HFD-580) 301-827-4230)

FDA Contacts: J. MERCIER (HFD-580) 301-827-4260 , Project Manager  
D. LIN (HFD-580) 301-827-4230 , Review Chemist  
M. RHEE (HFD-580) 301-827-4237 , Team Leader

Overall Recommendation: ACCEPTABLE on 23-SEP-1999 by S. FERGUSON (HFD-324) 301-827-0062

Establishment:



DMF No:

AADA:

Responsibilities: FINISHED DOSAGE RELEASE TESTER  
FINISHED DOSAGE STABILITY TESTER

Profile: CTL OAI Status: NONE

Estab. Comment: THIS SITE HAS HAD A SATISFACTORY CGMP INSPECTION WITHIN THE PAST TWO YEARS. (on 23-SEP-1999 by D. LIN (HFD-580) 301-827-4230)

Milestone Name	Date	Req. Type	Insp. Date	Decision & Reason	Creator
SUBMITTED TO OC	23-SEP-1999				LINDAV
OC RECOMMENDATION	23-SEP-1999			ACCEPTABLE BASED ON PROFILE	FERGUSONS

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**19-653/S-023 & 19-697/S-019**

**ADMINISTRATIVE and CORRESPONDENCE**  
**DOCUMENTS**



Food and Drug Administration  
Rockville MD 20857

NDA 19-697/S-019

The R. W. Johnson Pharmaceutical Research Institute  
920 Route 202 South  
P. O. Box 300  
Raritan, New Jersey 08869-0602

MAY 19 1999

Attention: Donna Panasewicz  
Director, Regulatory Affairs

Dear Ms. Panasewicz:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: ORTHO TRI-CYCLEN®

NDA Number: 19-697

Supplement Number: S-019

Date of Supplement: May 14, 1999

Date of Receipt: May 17, 1999

Unless we find the application not acceptable for filing, this application will be filed under Section 505(b)(1) of the Act on July 16, 1999 in accordance with 21 CFR 314.101(a).

All communications concerning this NDA should be addressed as follows:

Center for Drug Evaluation and Research  
Division of Reproductive and Urologic Drug Products, HFD-580  
Office of Drug Evaluation III  
Attention: Document Control Room 17B-20  
5600 Fishers Lane  
Rockville, MD 20857

Sincerely,

Terri F. Rumble  
Chief, Project Management Staff  
Division of Reproductive and Urologic  
Drug Products, HFD-580  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

NDA 19-697/S-019  
Page 2

cc:

Original NDA 19-697/S-019  
HFD-580/Div. Files  
HFD-580/CSO/Mercier

SUPPLEMENT ACKNOWLEDGEMENT

ORIGINAL

NDA NO. 19697 REF. NO. SCM-02  
NDA SUPPL FOR CBE sit



THE R.W. JOHNSON  
PHARMACEUTICAL RESEARCH INSTITUTE

ROUTE 202, P.O. BOX 300, RARITAN, NEW JERSEY 08869-0602

MAY 14 1999

Lisa Rarick, M.D.  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Reproductive and Urologic Drug  
Products, HFD-580  
Office of Drug Evaluation II  
Attn: Document Control Room 14B -03  
5600 Fishers Lane  
Rockville, Maryland 20857

NDA 19-653  
ORTHO-CYCLEN® Tablets  
(norgestimate/ethinyl estradiol)

Please cross refer to:

NDA 19-697  
ORTHO TRI-CYCLEN® Tablets  
(norgestimate/ethinyl estradiol)

**CHANGES BEING EFFECTED**  
**IN 30 DAYS**  
**PAC-ATLS Submission**

Dear Dr. Rarick:

Reference is made to the above listed approved New Drug Applications for our norgestimate and ethinyl estradiol oral contraceptive products. Pursuant to 21 CFR 314.70 (a) and the Guidance for Industry - PAC-ATLS: Postapproval Changes - Analytical Testing Laboratory Sites, we are hereby submitting, in duplicate, a Changes Being Effected In 30 Days Supplement to provide for an additional analytical testing laboratory site.

At this time, we are providing for the following analytical testing site to perform routine release, stability and validation (process, packaging, etc.) testing of ORTHO-CYCLEN® and ORTHO TRI-CYCLEN® Tablets by the methods described in NDA 19-653 and NDA 16-697:



We have determined that [ ] has the capability to perform testing by the current approved methods for this product. All postapproval commitments related to the test methods for the above referenced products have been fulfilled. [ ] has had a satisfactory current good manufacturing practice (CGMP) inspection within the past two (2) years.

NAORTHO\_CYLTR[ ]SUP399.DOC/1

In accordance with 21 CFR Part 314.70 (a), identical field copies of this supplemental application have been filed with our local FDA District Offices.

Should you have any questions or comments concerning this submission, please contact me directly at (908) 218-6140 or call our telephone line dedicated for FDA use at (908) 704-4600.

Sincerely,

The R. W. Johnson  
Pharmaceutical Research Institute



Donna Panasewicz  
Director  
Regulatory Affairs

REVIEWS COMPLETED	
CSO ACTION:	
<input type="checkbox"/> LETTER	<input type="checkbox"/> N.A.I. <input type="checkbox"/> MEMO
CSO INITIALS	DATE

Field Copy: Newark District Office, North Brunswick  
San Juan District Office, San Juan, Puerto Rico